REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
Location: United States, Maryland, Rockville
Employees: 201-500
Total raised: $123.53M
Founded date: 2008
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | F-Prime Ca... | fprimecapi... |
| - | Vivo Capit... | vivocapita... |
| - | Eight Road... | eightroads... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 05.01.2021 | - | $23.03M | - |
| 20.05.2015 | Series D | $70.5M | - |
| 21.01.2015 | Series C | $30M | - |
Mentions in press and media 35
| Date | Title | Description | Source |
| 12.03.2024 | Clearside Biomedical Announces Fourth Quarter and Full Year ... | - Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner ... | einpresswi... |
| 11.02.2023 | REGENXBIO Presents Interim Data from Phase II Bridging Study... | RGX-314 produced by the NAVXpress platform process has been well-tolerated and demonstrated a simila... | einpresswi... |
| 06.02.2023 | REGENXBIO Announces Presentations at the Angiogenesis, Exuda... | ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. RGNX today announced that three presenta... | einpresswi... |
| 08.12.2022 | REGENXBIO Announces Completion of Dosing in the Phase I/II T... | RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGE... | einpresswi... |
| 22.11.2022 | REGENXBIO to Participate in Upcoming Investor Conferences | ROCKVILLE, Md., Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. RGNX today announced it will participat... | einpresswi... |
| 08.02.2022 | REGENXBIO Announces Presentations at the 11th Annual SVB Lee... | ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will p... | marketscre... |
| 07.02.2022 | Athebio enters collaboration agreement in the field of gene ... | startuptic... | |
| 04.02.2022 | REGENXBIO Announces Presentations at the Angiogenesis, Exuda... | ROCKVILLE, Md., Feb. 4, 2022 /PRNewswire/ -- Data for Cohort 1 with six months of follow-up from the... | marketscre... |
| 31.01.2022 | REGENXBIO Announces Presentations at the 18th Annual WORLDSy... | ROCKVILLE, Md., Jan. 31, 2022 /PRNewswire/ -- Interim data from Phase I/II trials of RGX-121 for the... | marketscre... |
| 09.08.2021 | REGENXBIO Reports Second Quarter 2021 Financial Results and ... | prnewswire... |
Show more